About Kinarus Therapeutics Holding AG

Company Description

Kinarus is a clinical-stage biopharmaceutical company focused on bringing novel, patient-focused treatments to those suffering from viral, respiratory, and ophthalmic diseases.

Kinarus was incorporated as a private company in Basel, Switzerland in 2017. Its therapeutic drug candidate, KIN001, consists of an advanced clinical stage p38 MAPK inhibitor, in-licensed from Roche, combined with a marketed drug, together enabling an oral, long-term effective treatment for patients suffering from diseases with serious impact on quality of life.

Recently, in response to the global challenge of COVID-19, Kinarus has initiated clinical evaluation of its combination therapy to treat patients suffering from SARS-CoV-2 infection. Kinarus has discovered that KIN001 has anti-viral activity against SARS-CoV-2, including against its variants of concern. KIN001 also possesses anti-inflammatory and anti-fibrotic activity.

Year founded

2017

Served area

Worldwide

Headquarters

Hochbergerstrasse 60C, 4057 Basel – Switzerland

Shareholder information

Shares outstanding

1,069,533,039

IPO

June 3, 2022

Stock exchange(s)

SIX Swiss Exchange

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.